Drugs / SRX251
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00532467 | Sep 2007 → Feb 2008 | — | Azevan Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00461370 | Apr → Aug 2007 | — | Azevan Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRX251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00532467 ↗ |
| Action | Inhibit | “SRX251 is a new chemical entity with potent V1a receptor antagonist properties” NCT00461370 ↗1“Vasopressin V1a receptor antagonist” CHEMBL3545146 ↗ |
| Route | Oral | “single oral dose of SRX251” NCT00461370 ↗ |
| Target | AVPR1A | “Vasopressin V1a receptor antagonist” CHEMBL3545146 ↗ |